Press Release: LifeMD Reports Third Quarter 2026 Results

Dow Jones11-13
   -- Third quarter 2026 revenue of $44.6 million; adjusted EBITDA loss of 
      approximately $0.4 million, within the Company's guidance range of 
      negative $1 million to positive $2 million. 
 
   -- Adjusted EBITDA improved approximately $3.1 million sequentially from an 
      adjusted EBITDA loss of $3.5 million in the second quarter of 2026, 
      driven primarily by a 34% sequential reduction in selling and marketing 
      expenses and reduction of overall non-clinical expenses. 
 
   -- GAAP net loss from continuing operations attributable to common 
      stockholders of $5.2 million, or $0.11 per share, compared with $8.4 
      million, or $0.18 per share, in the second quarter of 2026. 
 
   -- Total active subscribers increased 13% year-over-year to approximately 
      350,000. 
 
   -- LifeMD Pharmacy shipment volume grew 58.3% year-over-year. 
 
   -- Exited the quarter with $21.9 million of cash and no debt; subsequent to 
      quarter-end, closed on a $12.5 million senior secured term loan to 
      replace the Company's previous credit facility. 
 
   -- Entered into arrangements with both Novo Nordisk and Eli Lilly, enabling 
      LifeMD's pharmacy to begin dispensing self-pay branded GLP-1 medications, 
      including Wegovy, Wegovy Pill, Ozempic, Zepbound, and Foundayo, to 
      patients nationwide. 
 
   -- Entered into an exclusive relationship with AT&T to provide its 100 
      million wireless and fiber customers and 110,000 U.S. employees access to 
      LifeMD's healthcare and pharmacy services. 
 
   -- Expecting fourth quarter 2026 revenue of between $46 million and $49 
      million, and Adjusted EBITDA of between negative $4 million to negative 
      $2 million. 

Conference call begins at 4:30 p.m. Eastern time today

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today reported financial results for the third quarter ended September 30, 2026.

Management Commentary

"We ended the quarter with approximately 350,000 active subscribers, up 13% from a year ago and nearly flat from the second quarter, despite spending $9.5 million less on marketing," said Justin Schreiber, Chairman and CEO of LifeMD. "We're helping more people access high-quality healthcare, and we're getting more efficient at doing it. From May to September, cost per acquisition fell 32% while monthly media spend declined 45%. Adjusted EBITDA improved approximately $3.1 million sequentially to roughly breakeven, and we expect to sustain or improve these unit economics going forward.

"Revenue of $44.6 million was below our guidance, and we are resetting our outlook for the fourth quarter and full year. We deliberately reduced marketing spend and prioritized longer patient commitments, and our partnerships took longer to ramp than we expected. Those factors weighed on revenue this quarter, but we believe our decisions put us in a stronger position to grow profitably.

"Our pharmacy has begun dispensing branded GLP-1 medications from Eli Lilly and Novo Nordisk. Our exclusive relationship with AT&T gives its 100 million wireless and fiber customers and 110,000 U.S. employees access to our healthcare and pharmacy services. We also made significant progress on our enterprise healthcare offering, which we will begin marketing to businesses across the country in the fourth quarter. Our women's health program continued to improve, and we added experienced leadership to accelerate its growth. Our focus now is turning this work into revenue growth while maintaining the operating discipline we established this quarter."

"Gross margin was approximately 82% in the quarter, compared with approximately 89% in the second quarter and 85% a year ago. The decline primarily reflects a change in presentation, not economics: under our new branded fulfillment arrangements, medications fulfilled by our own pharmacy are recognized on a gross revenue basis," said Atul Kavthekar, Chief Financial Officer of LifeMD. "We reduced selling and marketing expense by $9.5 million sequentially to $18.5 million. General and administrative expense increased slightly from the second quarter to $14.7 million, reflecting clinical capacity added to support our new partnerships, partially offset by efficiencies in non-clinical functions. We ended the quarter with $21.9 million of cash and no debt. Subsequent to quarter end, we closed a $12.5 million non-convertible senior secured term loan with Avenue Capital. It replaces our prior revolving credit facility and gives us significantly greater flexibility to fund the working capital our branded fulfillment arrangements may require."

Third Quarter 2026 Financial Highlights

All comparisons are with the third quarter of 2025 on a continuing operations basis (excluding WorkSimpli, which was divested on November 4, 2025, and is reported as discontinued operations for all periods presented). Non-GAAP financial measures referenced below are defined and reconciled to the most directly comparable GAAP measures at the end of this press release.

   -- Total revenue was $44.6 million, compared with $47.7 million in the 
      prior-year period, a decrease of approximately 7%. 
 
   -- Gross profit was $36.4 million, compared with $40.7 million in the 
      prior-year period. Gross margin was approximately 82%, compared with 
      approximately 85% in the prior-year period, a decline of approximately 
      370 basis points, primarily reflecting the gross revenue presentation of 
      branded medications fulfilled by our pharmacy. 
 
   -- Selling and marketing expenses decreased 18% year-over-year, and 34% 
      sequentially, to $18.5 million. 
 
   -- General and administrative expenses increased 6% year-over-year to $14.7 
      million, reflecting added clinical capacity. 
 
   -- GAAP net loss from continuing operations attributable to common 
      stockholders was $5.2 million, or $0.11 per share, compared with a GAAP 
      net loss from continuing operations attributable to common stockholders 
      of $5.4 million, or $0.12 per share, in the prior-year period. 
 
   -- Adjusted EBITDA was a loss of approximately $0.4 million, compared with 
      adjusted EBITDA of approximately $2.8 million in the prior-year period. 
 
   -- Cash totaled $21.9 million as of September 30, 2026, and the Company had 
      no debt at quarter end. 
 
   -- The number of active subscribers increased 13% year-over-year to 
      approximately 350,000 at quarter end. 
 
   ($ in 000s)          Three Months Ended September 30,           Y-o-Y 
                    ----------------------------------------      -------- 
 Key Performance 
     Metrics              2026                    2025            % Growth 
------------------  ----------------        ----------------      -------- 
 
Revenue              $        44,625         $        47,728            -7% 
 
Gross Profit         $        36,376         $        40,666           -11% 
 
Gross Margin %                    82%                     85%         -370bpts 
 
Adjusted EBITDA      $          (413)        $         2,787          -115% 
 
Active Subscribers           349,744                 310,818            13% 
 

Financial Guidance

For the fourth quarter of 2026, the Company expects:

   -- Revenue in the range of $46 million to $49 million. 
 
   -- Adjusted EBITDA in the range of negative $4 million to negative $2 
      million. 

For the full year 2026, the Company expects (revised from previous guidance):

   -- Revenue in the range of $188 million to $191 million, compared with 
      previous guidance of $205.5 million to $212.5 million. 
 
   -- Adjusted EBITDA in the range of negative $12.6 million to negative $10.6 
      million, compared with previous guidance of negative $6.0 million to 
      breakeven. 

Conference Call

LifeMD's management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company's financial results and outlook, and answer questions. Details for the call are as follows:

 
Toll-free dial-in number:                                (877) 270-2148 
International dial-in number:                         +1 (412) 902-6510 
Conference ID:                  LifeMD, Inc. Third Quarter 2026 Results 
 
 

A live and archived webcast will be available in the Investors section of the Company's website at ir.lifemd.com.

About LifeMD, Inc.

LifeMD(R) is a leading virtual care company making high-quality healthcare more accessible, convenient, and affordable. Through its vertically integrated platform, LifeMD connects patients with a 50-state affiliated medical group, laboratory services, a state-of-the-art in-house pharmacy, and a U.S.-based patient care center. Together, these capabilities support care across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. For more information, please visit LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: "believe," "expect," "anticipate, " "project," "should," "plan," "will," "may," "intend," "estimate," "predict," "continue," and "potential," or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded

products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, "Risk Factors" identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact

ir@lifemd.com

Media Contact

press@lifemd.com

Tables to Follow

 
                               LIFEMD, INC. 
                       CONSOLIDATED BALANCE SHEETS 
                               (Unaudited) 
 
                              September 30, 2026     December 31, 2025 
                             --------------------   ------------------- 
ASSETS 
 
Current Assets 
  Cash                        $        21,921,769    $       36,786,318 
  Receivables, net                     13,249,849             2,485,882 
  Product deposit                         218,690               320,217 
  Inventory, net                       10,348,601             2,773,576 
  Other current assets                  3,522,349             2,646,077 
    Total Current Assets               49,261,258            45,012,070 
 
Non-current Assets 
  Equipment, net                        1,905,154             2,444,717 
  Right of use assets, net              4,622,463             5,267,857 
  Capitalized software, net            10,329,573            10,604,946 
  Intangible assets, net                  166,583               262,334 
    Total Non-current 
     Assets                            17,023,773            18,579,854 
 
Total Assets                  $        66,285,031    $       63,591,924 
                                 ================       =============== 
 
LIABILITIES AND 
STOCKHOLDERS' (DEFICIT) 
EQUITY 
 
Current Liabilities 
  Accounts payable            $        37,736,899    $       14,149,154 
  Accrued expenses                     12,842,607            14,214,393 
  Current operating lease 
   liabilities                            691,719               642,422 
  Deferred revenue                     10,433,507            10,573,442 
                                 ----------------       --------------- 
    Total Current 
     Liabilities                       61,704,732            39,579,411 
 
Long-term Liabilities 
  Non-current operating 
   lease liabilities                    5,159,954             5,681,374 
    Total Liabilities                  66,864,686            45,260,785 
 
Commitments and 
Contingencies 
Stockholders' (Deficit) 
Equity 
  Series A Preferred Stock, 
   $0.0001 par value; 
   1,610,000 shares 
   authorized, 1,400,000 
   shares issued and 
   outstanding as of 
   September 30, 2026 and 
   December 31, 2025                          140                   140 
  Common Stock, $0.01 par 
   value; 100,000,000 
   shares authorized, 
   48,358,877 and 
   46,760,016 shares 
   issued, 48,255,837 and 
   46,656,976 outstanding 
   as of September 30, 2026 
   and December 31, 2025, 
   respectively                           483,589               467,600 
  Additional paid-in 
   capital                            255,443,609           251,455,616 
  Accumulated deficit                (256,343,292)         (233,428,516) 
  Treasury stock, 103,040 
   shares, at cost, as of 
   September 30, 2026 and 
   December 31, 2025                     (163,701)             (163,701) 
                                 ----------------       --------------- 
    Total LifeMD, Inc. 
     Stockholders' 
     (Deficit) Equity                    (579,655)           18,331,139 
    Total Liabilities and 
     Stockholders' 
     (Deficit) Equity         $        66,285,031    $       63,591,924 
                                 ================       =============== 
 
 
 
                               LIFEMD, INC. 
                   CONSOLIDATED STATEMENTS OF OPERATIONS 
                                (Unaudited) 
 
                     Three Months Ended       Nine Months Ended September 
                       September 30,                      30, 
                 --------------------------  ------------------------------ 
                    2026          2025           2026           2025 
                 -----------   -----------   ------------   ------------ 
Telehealth 
 revenue, net    $44,625,086   $47,727,942   $142,048,848   $146,861,697 
Cost of 
 telehealth 
 revenue           8,249,469     7,061,651     19,605,877     21,627,901 
 
Gross profit      36,375,617    40,666,291    122,442,971    125,233,796 
                  ----------    ----------    -----------    ----------- 
 
Expenses 
Selling and 
 marketing 
 expenses         18,500,609    22,563,994     76,411,416     66,988,030 
General and 
 administrative 
 expenses         14,654,524    13,800,377     43,468,661     42,995,255 
Other operating 
 expenses          3,453,051     2,800,013      9,673,184      8,072,564 
Customer 
 service 
 expenses          2,351,426     2,784,320      8,103,717      9,086,549 
Development 
 costs             1,882,508     1,844,269      5,470,005      5,526,379 
 
  Total 
   expenses       40,842,118    43,792,973    143,126,983    132,668,777 
                  ----------    ----------    -----------    ----------- 
 
Operating loss 
 from 
 continuing 
 operations       (4,466,501)   (3,126,682)   (20,684,012)    (7,434,981) 
 
Interest 
 (expense) 
 income, net          (3,212)     (260,621)        98,924     (1,385,046) 
Loss on debt 
 extinguishment            -    (1,155,851)             -     (1,155,851) 
 
Loss from 
 continuing 
 operations 
 before income 
 taxes            (4,469,713)   (4,543,154)   (20,585,088)    (9,975,878) 
 
Income tax 
 provision                 -       (31,823)             -        (31,823) 
                  ----------    ----------    -----------    ----------- 
Net loss from 
 continuing 
 operations       (4,469,713)   (4,574,977)   (20,585,088)   (10,007,701) 
 
Net income from 
 discontinued 
 operations                -       935,013              -      4,821,519 
 
Net loss          (4,469,713)   (3,639,964)   (20,585,088)    (5,186,182) 
 
Net income 
 attributable 
 to 
 noncontrolling 
 interests of 
 discontinued 
 operations                -       249,462              -      1,286,382 
                  ----------    ----------    -----------    ----------- 
 
Net loss 
 attributable 
 to LifeMD, 
 Inc.             (4,469,713)   (3,889,426)   (20,585,088)    (6,472,564) 
 
Preferred stock 
 dividends          (776,563)     (776,563)    (2,329,688)    (2,329,688) 
 
Net loss 
 attributable 
 to LifeMD, 
 Inc. common 
 stockholders    $(5,246,276)  $(4,665,989)  $(22,914,776)  $ (8,802,252) 
                  ==========    ==========    ===========    =========== 
 
Basic (loss) 
earnings per 
share 
attributable to 
LifeMD, Inc. 
common 
stockholders 
  Continuing 
   operations    $     (0.11)  $     (0.12)  $      (0.48)  $      (0.28) 
  Discontinued 
   operations              -          0.01              -           0.08 
 
  Basic loss 
   per share     $     (0.11)  $     (0.10)  $      (0.48)  $      (0.20) 
                  ==========    ==========    ===========    =========== 
 
Diluted (loss) 
earnings per 
share 
attributable to 
LifeMD, Inc. 
common 
stockholders 
  Continuing 
   operations    $     (0.11)  $     (0.12)  $      (0.48)  $      (0.28) 
  Discontinued 
   operations              -          0.01              -           0.08 
 
  Diluted loss 
   per share     $     (0.11)  $     (0.10)  $      (0.48)  $      (0.20) 
                  ==========    ==========    ===========    =========== 
 
Weighted 
average number 
of common 
shares 
outstanding: 
  Basic           48,182,152    46,162,625     47,772,180     44,575,553 
                  ==========    ==========    ===========    =========== 
  Diluted         48,182,152    46,162,625     47,772,180     44,575,553 
                  ==========    ==========    ===========    =========== 
 
 
 
                                 LIFEMD, INC. 
                     CONSOLIDATED STATEMENTS OF CASH FLOWS 
                                  (Unaudited) 
 
                       Three Months Ended        Nine Months Ended September 
                          September 30,                      30, 
                   ---------------------------  ------------------------------ 
                      2026           2025           2026           2025 
                   -----------   ------------   ------------   ------------ 
 
CASH FLOWS FROM 
OPERATING 
ACTIVITIES 
Net loss           $(4,469,713)  $ (3,639,964)  $(20,585,088)  $ (5,186,182) 
Less: Net income 
 from 
 discontinued 
 operations                  -        935,013              -      4,821,519 
                    ----------    -----------    -----------    ----------- 
Net loss from 
 continuing 
 operations         (4,469,713)    (4,574,977)   (20,585,088)   (10,007,701) 
Adjustments to 
reconcile net 
loss from 
continuing 
operations to net 
cash (used in) 
provided by 
operating 
activities: 
  Amortization of 
   debt discount             -         33,481              -        234,369 
  Amortization of 
   capitalized 
   software          1,727,834      1,597,030      5,116,366      4,712,732 
  Amortization of 
   intangibles          31,917         31,917         95,751         62,084 
  Loss on debt 
   extinguishment            -      1,155,851              -      1,155,851 
  Depreciation of 
   fixed assets        301,049        253,031        883,294        583,915 
  Noncash 
   operating 
   lease expense       217,495        217,495        645,394        743,207 
  Stock 
   compensation 
   expense           1,684,445      3,198,036      3,923,462      7,841,178 
 
Changes in Assets 
and Liabilities 
  Receivables       (9,507,862)       (10,338)   (10,763,967)     2,618,396 
  Product deposit       25,069       (119,518)       101,527       (329,755) 
  Inventory         (7,392,457)      (181,027)    (7,575,025)      (635,024) 
  Other current 
   assets           (1,035,546)    (1,382,528)      (876,272)      (558,239) 
  Operating lease 
   liabilities        (165,451)       (23,535)      (472,123)      (171,841) 
  Deferred 
   revenue            (357,714)    (2,322,589)      (139,935)    (4,864,738) 
  Accounts 
   payable          19,579,987     (4,591,851)    23,587,745      3,896,078 
  Accrued 
   expenses         (1,588,687)     4,529,660     (1,371,786)    (1,109,939) 
    Net cash 
     (used in) 
     provided by 
     operating 
     activities 
     of 
     continuing 
     operations       (949,634)    (2,189,862)    (7,430,657)     4,170,573 
    Net cash 
     provided by 
     operating 
     activities 
     of 
     discontinued 
     operations              -      2,042,726              -      7,390,125 
    Net cash 
     (used in) 
     provided by 
     operating 
     activities       (949,634)      (147,136)    (7,430,657)    11,560,698 
                    ==========    ===========    ===========    =========== 
 
CASH FLOWS FROM 
INVESTING 
ACTIVITIES 
Cash paid for 
 capitalized 
 software costs     (1,322,921)    (1,937,544)    (4,840,993)    (5,884,672) 
Purchase of 
 equipment            (170,728)      (785,748)      (343,731)    (1,679,963) 
    Net cash used 
     in investing 
     activities 
     of 
     continuing 
     operations     (1,493,649)    (2,723,292)    (5,184,724)    (7,564,635) 
    Net cash used 
     in investing 
     activities 
     of 
     discontinued 
     operations              -       (871,188)             -     (2,596,766) 
                                  ----------- 
    Net cash used 
     in investing 
     activities     (1,493,649)    (3,594,480)    (5,184,724)   (10,161,401) 
                    ==========    ===========    ===========    =========== 
 
CASH FLOWS FROM 
FINANCING 
ACTIVITIES 
Repayment of debt 
 instruments                 -    (16,667,433)             -    (18,719,721) 
Sale of common 
 stock under ATM, 
 net                         -      8,721,717              -      8,721,717 
Preferred stock 
 dividends            (776,563)      (776,563)    (2,329,688)    (2,329,688) 
Cash proceeds 
 from exercise of 
 warrants                    -        464,950              -        464,950 
Cash proceeds 
 from exercise of 
 options                     -          5,950         80,520          5,950 
    Net cash used 
     in financing 
     activities 
     of 
     continuing 
     operations       (776,563)    (8,251,379)    (2,249,168)   (11,856,792) 
    Net cash used 
     in financing 
     activities 
     of 
     discontinued 
     operations              -       (449,539)             -       (761,658) 
    Net cash used 
     in financing 
     activities       (776,563)    (8,700,918)    (2,249,168)   (12,618,450) 
                    ==========    ===========    ===========    =========== 
 
Net decrease in 
 cash               (3,219,846)   (12,442,534)   (14,864,549)   (11,219,153) 
Cash at beginning 
 of period          25,141,615     36,228,305     36,786,318     35,004,924 
Cash at end of 
 period             21,921,769     23,785,771     21,921,769     23,785,771 
Less: Cash of 
 discontinued 
 operations at 
 end of period               -      2,838,484              -      2,838,484 
Cash of 
 continuing 
 operations at 
 end of period     $21,921,769   $ 20,947,287   $ 21,921,769   $ 20,947,287 
                    ==========    ===========    ===========    =========== 
 
Cash paid for 
interest and 
taxes 
----------------- 
Cash paid during 
 the period for 
 interest          $         -   $    241,464   $          -   $  1,461,032 
                    ==========    ===========    ===========    =========== 
Cash paid during 
 the period for 
 taxes             $         -   $     14,617   $    361,230   $    482,471 
                    ==========    ===========    ===========    =========== 
 
Non-cash 
investing and 
financing 
activities 
----------------- 
Cashless exercise 
 of options        $         -   $        253   $          -   $      1,315 
                    ==========    ===========    ===========    =========== 
Cashless exercise 
 of warrants       $     3,204   $          -   $      3,204   $      3,901 
                    ==========    ===========    ===========    =========== 
Stock issued for 
 debt conversion   $         -   $          -   $          -   $  1,000,000 
                    ==========    ===========    ===========    =========== 
Stock issued for 
 asset 
 acquisition       $         -   $          -   $          -   $    303,000 
                    ==========    ===========    ===========    =========== 
 
 

About the Use of Non-GAAP Financial Measures

To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of this financial measure enhances an investor's understanding of our financial performance. We further believe that this financial measure is a useful financial metric to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.

Adjusted EBITDA is defined as net loss attributable to LifeMD, Inc. common stockholders before interest, taxes, depreciation, amortization, extraordinary litigation costs, severance and restructuring costs, acquisition expenses, insurance acceptance readiness expenses, preferred stock dividends, stock-based compensation expense, net income from discontinued operations and net income attributable to noncontrolling interests of discontinued operations. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to LifeMD, Inc. common stockholders, its most directly comparable GAAP financial measure.

We believe the above financial measure is commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.

 
Reconciliation of Net Loss Attributable to LifeMD, 
 Inc. Common Stockholders to Adjusted EBITDA 
(in whole numbers, 
unaudited) 
                         Three Months Ended       Nine Months Ended September 
                           September 30,                      30, 
                     --------------------------  ----------------------------- 
                        2026          2025           2026          2025 
                     -----------   -----------   ------------   ----------- 
Net loss 
 attributable to 
 LifeMD, Inc. 
 common 
 stockholders        $(5,246,276)  $(4,665,989)  $(22,914,776)  $(8,802,252) 
 
Interest (income) 
 expense, net              3,212       227,140        (98,924)    1,150,677 
Depreciation and 
 amortization 
 expense               2,060,800     1,881,978      6,095,411     5,358,731 
Amortization of 
 debt discount                 -        33,481              -       234,369 
Loss on debt 
 extinguishment                -     1,155,851              -     1,155,851 
Financing 
 transactions 
 expense                       -        97,699              -        97,699 
Litigation costs 
 (a)                      64,328       959,803      1,112,269     1,699,462 
Severance and 
 restructuring 
 costs                   243,885             -        992,879       102,417 
Acquisitions 
 expenses                      -      (231,571)             -     1,783,206 
Insurance 
 acceptance 
 readiness                     -         8,190              -       183,330 
Taxes                          -        31,823              -        31,823 
Preferred stock 
 dividends               776,563       776,563      2,329,688     2,329,688 
Stock compensation 
 expense               1,684,445     3,198,036      3,923,462     7,841,178 
Net income from 
 discontinued 
 operations                    -      (935,013)             -    (4,821,519) 
Net income 
 attributable to 
 noncontrolling 
 interests of 
 discontinued 
 operations                    -       249,462              -     1,286,382 
 
Adjusted EBITDA      $  (413,043)  $ 2,787,452   $ (8,559,991)  $ 9,631,041 
                      ==========    ==========    ===========    ========== 
 
(a) For the three and nine months ended September 
 30, 2026 and 2025, the Company included costs related 
 to: (1) a class action complaint captioned Johnston 
 v. LifeMD, Inc., et al., against the Company and certain 
 executive officers alleging: (i) violations of Section 
 10(b) of the Securities Exchange Act of 1934, as amended, 
 and Rule 10b-5 promulgated thereunder by all defendants 
 for making false and misleading statements; and (ii) 
 violations of Section 20(a) of the Securities Exchange 
 Act of 1934, as amended, by the individual officer 
 defendants for violating their duty to disseminate 
 accurate and truthful information, and (2) a heavily 
 negotiated executive separation agreement. For the 
 three and nine months ended September 30, 2025, the 
 Company also included costs related to a class action 
 complaint alleging, inter alia, unauthorized disclosure 
 of certain information of class members to third parties 
 (the Marden v. LifeMD, Inc. case). 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment